Sonnet BioTherapeutics Holdings Inc [NASDAQ: SONN] jumped around 2.94 points on Wednesday, while shares priced at $4.15 at the close of the session, up 242.98%.
Compared to the average trading volume of 44.93K shares, SONN reached a trading volume of 128360872 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sonnet BioTherapeutics Holdings Inc [SONN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SONN shares is $20.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SONN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 19.57, with the Price to Cash per share for the same quarter was set at 0.65.
How has SONN stock performed recently?
Sonnet BioTherapeutics Holdings Inc [SONN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 267.26. With this latest performance, SONN shares gained by 254.70% in over the last four-week period, additionally plugging by 174.83% over the last 6 months – not to mention a rise of 184.25% in the past year of trading.
Sonnet BioTherapeutics Holdings Inc [SONN]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sonnet BioTherapeutics Holdings Inc [SONN] shares currently have an operating margin of -1376.89% and a Gross Margin at 91.31%. Sonnet BioTherapeutics Holdings Inc’s Net Margin is presently recorded at -1328.60%.
Return on Equity for this stock declined to -272.65%, with Return on Assets sitting at -272.65%.
